Geisinger and Terumo Neuro Advance Stroke Education and Neurovascular Innovation in Recognition of World Stroke Day 2025
MWN-AI** Summary
In recognition of World Stroke Day 2025, Geisinger and Terumo Neuro have launched a significant educational initiative focused on advancing stroke awareness and treatment. The collaboration emphasizes the critical importance of early stroke recognition and the role of innovative, minimally invasive neurovascular treatments. A highlight of this campaign is the release of an educational video, "Transforming Neurovascular Stroke Care: Geisinger and Physician Innovation in Action," featuring Dr. Oded Goren, a leading expert in minimally invasive stroke treatments at Geisinger Medical Center.
As stroke remains one of the leading causes of death and long-term disability, the initiative underscores the need for greater public awareness regarding stroke warning signs, encapsulated in the B.E.F.A.S.T. acronym (Balance, Eyes, Face drooping, Arm weakness, Speech difficulty, Time to call 911). The campaign also focuses on expanding access to care, particularly in rural communities where stroke centers may be scarce.
Geisinger’s integrated care model serves as a blueprint for providing advanced neurovascular interventions closer to home, showcasing how innovative technologies like the WEB™ Embolization System can improve patient outcomes. Terumo Neuro's commitment to education and innovation aligns with Geisinger’s leadership, aiming to reduce disparities in stroke treatment throughout the nation.
CEO Carsten Schroeder of Terumo Neuro expressed pride in collaborating with Geisinger to highlight how physician leadership and advanced medical technology can advance stroke care. This partnership is expected to empower communities and drive forward a shared mission of improving healthcare outcomes for stroke patients across diverse populations.
MWN-AI** Analysis
**Market Analysis and Investment Advice: Geisinger and Terumo Neuro's Stroke Initiative**
As we observe World Stroke Day 2025, the collaboration between Geisinger and Terumo Neuro provides a significant opportunity for investors to consider the sector of neurovascular treatment and its growing awareness. This initiative, highlighting minimally invasive treatments and education, underscores a pivotal shift towards improving patient outcomes in stroke care—a condition that remains a leading cause of death and disability globally.
Geisinger's established reputation in value-based healthcare, combined with Terumo Neuro's innovative technological prowess, forms a compelling case for market growth in this sector. Their efforts to promote early stroke recognition using educational campaigns such as B.E.F.A.S.T. reflect a broader trend toward preventive healthcare. This focus on education not only improves patient outcomes but also promotes community health, potentially driving higher patient volumes to Geisinger's facilities.
Investors should closely monitor Geisinger's financial health; with over $8 billion in annual revenues and a strong presence in rural healthcare, its successful integration of advanced neurovascular interventions can offer a stable growth trajectory. Furthermore, as Geisinger diversifies its offerings, its partnership with Terumo could enhance its procedural volume through the introduction of advanced devices like the WEB™ Embolization System, further bolstering revenue streams.
On the other side, Terumo Neuro's commitment to innovation and its existing global reach present a promising outlook for expansion in emerging markets. The demand for innovative neurovascular solutions is expected to grow due to increasing awareness of stroke risks and advances in medical technology.
In conclusion, both Geisinger and Terumo Neuro showcase a strategic alignment that not only positions them well in a growing market but also addresses critical healthcare needs. Investors are advised to consider opportunities within companies that emphasize innovation in healthcare, particularly in neurovascular spaces, as they are likely to benefit from both consumer demand and the shift towards value-based care in the coming years.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Collaboration Highlights Minimally Invasive Neurovascular Stroke Treatment and Expands Public Awareness on Early Recognition and Access to Care
DANVILLE, Pa. and ALISO VIEJO, Calif., Oct. 29, 2025 /PRNewswire/ -- In honor of World Stroke Day 2025, Geisinger and Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, will release an educational video and awareness campaign emphasizing the importance of early stroke recognition, rapid treatment, and minimally invasive innovation in neurovascular care.
Filmed onsite at Geisinger Medical Center in Danville, PA, the video, "Transforming Neurovascular Stroke Care: Geisinger and Physician Innovation in Action," spotlights Dr. Oded Goren, Director of Open Vascular and Endovascular Neurosurgery at Geisinger Medical Center and Associate Professor of Neurosurgery, Geisinger Commonwealth School of Medicine, whose pioneering work in minimally invasive neurovascular stroke treatment has positioned the health system as a regional leader in advanced stroke care.
"Stroke remains one of the leading causes of death and long-term disability, yet many people still don't recognize its early signs," said Dr. Goren. "At Geisinger, we are committed to expanding access to high-quality, minimally invasive care for every patient—regardless of where they live. World Stroke Day gives us the opportunity to educate, empower, and inspire action that can truly save lives."
The initiative builds on last year's World Stroke Day 2024 collaboration between Terumo Neuro and Tulane University School of Medicine, which featured Dr. Kendrick Johnson advocating for equitable healthcare access and stroke education. This year, Terumo Neuro is continuing that mission—spotlighting Geisinger's leadership in physician innovation, rural access, and patient-centered education.
Key Campaign Themes
- Advancing Minimally Invasive Stroke Treatment: Geisinger physicians are leveraging technologies such as the WEB™ Embolization System to treat complex brain aneurysms and prevent hemorrhagic strokes.
- Educating Communities: The campaign emphasizes the importance of recognizing stroke warning signs early—using the B.E.F.A.S.T. acronym (Balance, Eyes, Face drooping, Arm weakness, Speech difficulty, Time to call 911)—and acting immediately.
- Expanding Access to Care: With many rural areas lacking nearby stroke centers, Geisinger's integrated care model demonstrates how community hospitals can provide advanced neurovascular interventions closer to home.
- Collaborating for Better Outcomes: By combining clinical excellence with Terumo Neuro's commitment to education and innovation, this initiative aims to reduce disparities in stroke treatment and improve outcomes for patients nationwide.
"We are honored to collaborate with Geisinger and Dr. Goren to bring greater visibility to stroke awareness and innovation," said Carsten Schroeder, CEO, Terumo Neuro. "Together, we are highlighting how physician leadership and medical technology can change what's possible in stroke care—reinforcing our shared commitment to improving patient outcomes around the world."
About Geisinger
Geisinger is among the nation's leading providers of value-based care, serving 1.2 million people in urban and rural communities across central and northeastern Pennsylvania. Founded in 1915 by philanthropist Abigail Geisinger, the nonprofit system generates more than $8 billion in annual revenues across 163 care sites — including 10 hospital campuses — and Geisinger Health Plan, with more than half a million members in commercial and government plans. Geisinger College of Health Sciences educates more than 5,000 medical professionals annually and is conducting more than 1,400 clinical research studies. With more than 27,000 employees, including 1,800 employed physicians and 5,200 registered nurses, Geisinger is among Pennsylvania's largest employers, having an estimated economic impact of $16.8 billion on the state's economy. In 2024, Geisinger joined Risant Health, a nonprofit charitable organization created to expand and accelerate value-based care across the country. Learn more at geisinger.org or follow on Facebook, Instagram and LinkedIn.
About Terumo Neuro
We're in business to create and deliver innovations that redefine what's possible in neurovascular treatment, meaningfully advancing both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in Aliso Viejo, California, Terumo Neuro products are sold in more than seventy countries through a dedicated sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information, please visit www.terumoneuro.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for more than 100 years. Based in Tokyo and operating globally, Terumo employs over 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company began as a Japanese thermometer manufacturer and now offers an extensive portfolio—from vascular intervention and cardio-surgical solutions to blood transfusion, cell therapy technology, and essential clinical products.
Media Contacts:
Kristin Machacek Leary
Chief People Officer & Head of Global Communications
Terumo Neuro
+ 1 617 230 1935
kristin.leary@microvention.com
John J. Grabusky
Senior Director, System Marketing & Community Engagement
Geisinger
jjgrabusky@geisinger.edu
SOURCE Terumo Neuro
FAQ**
How does the collaboration between Geisinger and Terumo Neuro leverage innovations from Terumo Corporation ADR TRUMY to enhance minimally invasive stroke treatment options?
In what specific ways does Geisinger's integrated care model aim to improve access to neurovascular interventions in rural areas, in partnership with Terumo Corporation ADR TRUMY?
How does the B.E.F.A.S.T. educational campaign support public awareness of early stroke recognition, and what role does Terumo Corporation ADR TRUMY play in this initiative?
What outcomes have been observed from Geisinger's leadership in advanced stroke care, particularly with innovations from Terumo Corporation ADR TRUMY, in addressing healthcare disparities nationwide?
**MWN-AI FAQ is based on asking OpenAI questions about Terumo Corporation ADR (OTC: TRUMY).
NASDAQ: TRUMY
TRUMY Trading
3.44% G/L:
$12.785 Last:
115,144 Volume:
$12.80 Open:
